# Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011)

> **NCT01624974** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 107 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** MK-1029
- **DRUG:** Placebo
- **DRUG:** Montelukast (ML)

## Key facts

- **NCT ID:** NCT01624974
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-09
- **Primary completion:** 2014-05-05
- **Final completion:** 2014-05-05
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2019-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01624974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01624974, "Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01624974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*